drug
abemaciclib
Marketedupdated 6mo agoby Eli Lilly and Co
Approvedannual revenue · 2024–2024peak $5.2B
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying abemaciclib
- phase2A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
- phase1A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- phase3Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- EP1(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- phase2A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- phase2A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- phase2A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 28, 2031
~4.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Sep 28, 2031compositionUS 78552114.9y
- Sep 28, 2031compositionUS 78552114.9y
- Sep 28, 2031compositionUS 78552114.9y
- Sep 28, 2031compositionUS 78552114.9y
News(7)
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideAlkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.biopharma_dive · 1mo ago
- AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketSERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.biospace · 2mo ago
- AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerThe approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…biospace · 2mo ago
- FDA Grants Accelerated Approval to a New Breast Cancer TreatmentThe U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…fda_press · 2mo ago
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.biopharma_dive · 5mo ago
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…endpoints · 5mo ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that